HighTower Advisors LLC Has $428,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

HighTower Advisors LLC cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,956 shares of the specialty pharmaceutical company’s stock after selling 441 shares during the quarter. HighTower Advisors LLC’s holdings in Collegium Pharmaceutical were worth $428,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. TD Private Client Wealth LLC increased its position in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 483 shares during the period. Virtus Fund Advisers LLC bought a new stake in Collegium Pharmaceutical during the third quarter valued at $72,000. KBC Group NV grew its holdings in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Collegium Pharmaceutical by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 642 shares during the period.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at $4,330,048.32. The trade was a 20.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the sale, the chief financial officer now owns 177,195 shares of the company’s stock, valued at approximately $5,315,850. The trade was a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock worth $3,243,594 over the last three months. 3.98% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on COLL shares. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. Finally, Piper Sandler lowered their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Trading Up 0.5 %

Shares of Collegium Pharmaceutical stock opened at $29.85 on Tuesday. The stock has a market capitalization of $939.86 million, a PE ratio of 12.87 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The stock has a 50 day moving average price of $30.29 and a two-hundred day moving average price of $32.35. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.